Revenue
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Limited Company (HIK)
Price£15.31Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $3.35B | $3.13B | $2.88B | $2.52B | $2.55B | $2.34B |
| Gross profit | $1.44B | $1.42B | $1.39B | $1.24B | $1.30B | $1.20B |
| Gross margin | 43.03% | 45.25% | 48.35% | 49.19% | 50.96% | 51.30% |
| Research & development | $151.0M | $141.0M | $149.0M | $144.0M | $143.0M | $137.0M |
| Operating expenses | $899.0M | $803.0M | $1.02B | $956.0M | $719.0M | $622.0M |
| Operating income | $542.0M | $612.0M | $367.0M | $282.0M | $582.0M | $579.0M |
| Operating margin | 16.18% | 19.57% | 12.77% | 11.20% | 22.80% | 24.73% |
| EBITDA | $845.0M | $698.0M | $552.0M | $485.0M | — | — |
| EBITDA margin | 25.23% | 22.32% | 19.20% | 19.27% | — | — |
| Net income | $407.0M | $362.0M | $192.0M | $191.0M | $420.0M | $430.0M |
| Net profit margin | 12.15% | 11.58% | 6.68% | 7.59% | 16.45% | 18.37% |
| Basic EPSper basic share | $1.82 | $1.62 | $0.86 | $0.84 | $1.82 | $1.83 |
| Diluted EPSper diluted share | $1.81 | $1.61 | $0.85 | $0.84 | $1.81 | $1.81 |
Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...